The Battle for This Huge Market Just Got Hotter

With Zimmer's acquisition of Biomet, this orthopedics company rises into the top tier of device makers and squares off against some formidable rivals.

Apr 25, 2014 at 6:30PM

The orthopedics industry's become a huge force in health care as populations in some of the world's biggest markets age and experience wear and tear on joints. Companies like Zimmer Holdings (NYSE:ZMH) and Stryker (NYSE:SYK) have reaped billions of dollars in revenue from orthopedics devices, and new, innovative technologies such as MAKO Surgical's RIO robotic surgical system, which Stryker snapped up in its acquisition of the company last year, are bringing new frontiers into this massive market.

Among the top companies, however, competition's fierce -- and Zimmer only added fuel to the fire of this war for dominance on Thursday when it announced an industry-shaking acquisition of rival Biomet. The big-time buy vaults Zimmer into the discussion of the top company in orthopedics, but will Biomet help Zimmer's stock outrun its rivals in the long term?

Zimmer's big play for the future
Zimmer forked over more than $13 billion in cash and stock in Thursday's deal for Biomet that shook up the market. It's an industry-shaking move: Combined, the two companies reported revenue of around $7.8 billion, placing the new Zimmer in the same class as Stryker and Johnson & Johnson's (NYSE:JNJ) DePuy as the clear-cut leaders by sales in the orthopedics industry. Previously, Zimmer had been the fourth-largest orthopedics producer; analysts expect that the merger will propel the company to the second spot behind only J&J. Investors certainly rallied behind the stock, sending shares shooting up more than 11% and turning Zimmer into one of the best buys among the top orthopedics device leaders over the past year.

ZMH Chart

ZMH data. Source: YCharts.

It's also promising for Zimmer's future outlook. While it will naturally see a boost to earnings in the year following the deal's close, Zimmer also projects that it will gain $270 million in savings in the third year and beyond following the acquisition. That'll help the company as it works toward improving profitability, something it failed to do last year as its operating margin declined by a full percentage point even as it lowered R&D and SG&A costs.

For investors and this stock, however, it's crucial that Zimmer capture the synergies of the Biomet acquisition particularly in its reconstructive orthopedics division. The business makes up around three-fourths of Zimmer's overall sales, split between knee, hip, and extremities products -- each of which has managed to ride the demographic trends buoying the market's optimism to respectable annual growth in sales last year.

Jj Logo

Will the top orthopedics players fire back?
Still, Zimmer has its work cut out for it. Competition will only grow hotter as the company's acquisition puts pressure on competitors to generate growth of their own, whether organically or through buyouts. Acquisitions, after all, spurred the growth of Johnson & Johnson's own medical device business when it purchased orthopedics and trauma products producer Synthes in 2011 for more than $21 billion. The synergies from that deal have powered orthopedics to the top of J&J's device business and managed 2.5% year-over-year growth in the most recent quarter.

While J&J likely will be content to remain in its top position in the orthopedics industry, Stryker and Smith & Nephew (NYSE:SNN) could be more active following Zimmer's deal. Stryker's already made big moves on the buyout front lately, from the MAKO buy to ride the cutting edge of the industry to last year's purchase of China's Trauson Holdings, giving Stryker an easy route into the world's second-largest economy. Smith & Nephew's also been active on the international front, with its emerging markets division now making up a full 13% of total revenue after 18% sales growth in 2013. Biomet's buyout has raised consideration now among analyst groups that Smith & Nephew could be the acquisitions target of Stryker or J&J in the near future, and Zimmer will need to keep growth churning along in order to keep up.

It's overseas that Zimmer investors need to keep a close eye on. China's orthopedics market has averaged around 20% compound annual growth in past years, and growth's likely to remain high with the rise of urbanization and the middle class in the country. Meanwhile, Zimmer's Asia-Pacific revenue in knee and hip reconstructive products fell in 2013, a trend it will need to turn around to keep geographic growth on course and investors happy about its future in emerging markets.

A fight for market share intensifies
While Zimmer still has work to do to show it can keep up with the likes of J&J's DePuy unit, the acquisition of Biomet plants this medical device leader squarely among the giants of the orthopedics industry. Demographic trends in the U.S., Europe, Japan, and China -- if Zimmer can capture that last market -- will only keep the market growing for the company and its rivals. As the market concentrates on the biggest players -- a trend that could be exacerbated should Stryker or J&J move on a Smith & Nephew acquisition in the coming years -- Zimmer will have to fight tooth and nail for market share. The buyout of Biomet's a good first step, but it's only the beginning for this device leader.

Will this stock be your next 10-bagger?
Savvy investors are always on the hunt for stocks that could boom like Zimmer did on Thursday, but one pick in particular could rule the market this year. Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with amazing potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303%! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. It also owns shares of Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information